ClinicalTrials.gg
Not yet recruitingNCT07872306Updated Oct 13, 2026

A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

A Phase 2 interventional study of forazapadin and Placebo Comparator in Facioscapulohumeral Muscular Dystrophy (FSHD), sponsored by Satellos Bioscience, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Satellos Bioscience, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a two-part, Phase 2, randomized, placebo-controlled, double-blind study, followed by a randomized active treatment period, to evaluate the safety and efficacy of orally administered forazapadin (SAT-3247) in adult participants with FSHD

02

Conditions studied

  • Facioscapulohumeral Muscular Dystrophy (FSHD)
03

In context

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

This study's planned enrollment of 51 is close to the median of 48 across 49 interventional studies indexed under Muscular Dystrophy, Facioscapulohumeral.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Lead sponsor

Satellos Bioscience, Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • definitive diagnosis of FSHD1 or FSHD2, confirmed by clinical findings and prior genetic testing results
  • presence of weakness in upper limbs at Screening, defined as a Brooke score ≥ 2
  • presence of weakness in a lower limb at Screening, defined as a MRC score of ≤4 on ankle dorsiflexion
  • ambulatory at Screening
  • if taking herbal remedies and supplements which can impact muscle strength and function, must maintain a stable regimen for the duration of the trial
  • if taking prescription medicines, over-the-counter medicines and/or herbal supplements for supportive care, doses should be stable for ≥ 1 month prior to the Screening Visit and remain stable for the duration of the trial
  • if on a physical therapy/strength training regimen, the regimen must be stable for ≥ 2 months prior to the Screening Visit and remain stable for the duration of the trial
  • ability to provide written
  • all participants, if sexually active, agree to follow the requirements and sperm donation limitations

Exclusion criteria

Exclusion Criteria:

  • ambulatory participants expected to experience loss of ambulation within ≤ 12 months
  • medical condition, other than FSHD, that would impact ambulation or ability to perform the functional assessments
  • presence of acute or chronic illness, or history of chronic illness (other than FSHD)
  • prior or ongoing medical condition, medical history, physical examination findings, findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant
  • evidence of renal impairment at Screening, including renal impairment demonstrated by cystatin C-based estimated (eGFR) \<60 mL/min/1.73m², a history of renal disease, or current acute kidney injury or acute kidney injury
  • evidence of significant hepatic dysfunction, defined as glutamate dehydrogenase (GLDH) >2× (ULN) at the Screening Visit, or known hepatic impairment classified as Class B (moderate) or Child-Pugh Class C (severe)
  • history of seizures or seizure-like events
  • surgery (e.g., stomach bypass) or medical condition that might affect absorption of medicines
  • acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, heartburn) or acute infection (such as influenza) or a significant infection or known inflammatory process at Screening
  • presence or history of severe adverse reaction to any in the study drug tablets
  • treatment with another drug or biological agent within 30 days or 5 half-lives of the investigational drug or biological agent
  • received SAT-3247 in another study
  • positive test for surface antigen (HBsAg), (HCV) antibody or (HIV)
  • current or expected use during the study of any medications that are known to be strong or moderate inhibitors of Cytochrome P450 isoform 3A4 ()
  • treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist within 3 months prior to Screening
  • consumption of grapefruit, grapefruit juice, and grapefruit-containing products
  • employee, contractors, or consultants of the Sponsor, the contract research organization (CRO), and/or study site or their relatives
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
51 participants (estimated)

Study arms

  • Active comparator
    forazapadin (SAT-3247) 60 mg

    Drug: forazapadin · Drug: Placebo Comparator

  • Active comparator
    forazapadin (SAT-3247) 120 mg

    Drug: forazapadin · Drug: Placebo Comparator

  • Placebo comparator
    placebo

    Drug: Placebo Comparator

Interventions

  • Drugforazapadin

    Forazapadin (SAT 3247) is a potent, orally available, muscle penetrant, small molecule inhibitor of AAK1

  • DrugPlacebo Comparator

    Matching placebo oral tablets

06

What researchers measure

Primary outcomes

  1. Safety evaluation of forazapadin in FSHD

    Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs)

    Time frame: 48 weeks

  2. Efficacy of forazapadin as treatment in FSDH

    Change in muscle force measurements as determined by dynamometry

    Time frame: 24 and 48 weeks

Secondary outcomes

  1. Effects of forazapadin on muscle MRI

    Whole-body MRI will be utilized as a non-invasive, quantitative imaging modality to assess skeletal muscle composition across participants. MRI will be used to measure muscle fat fraction (MFF) and characterize the extent of muscle fat infiltration (MFI)

    Time frame: 24 and 48 weeks

  2. Pharmacokinetic (PK) profile

    Determine the pharmacokinetic (PK) profile of SAT-3247 in participants with FSHD calculating maximum concentration (Cmax)

    Time frame: 24 weeks

  3. Pharmacokinetic (PK) profile

    Determine the pharmacokinetic (PK) profile of SAT-3247 in participants with FSHD calculating time to maximum concentration (Tmax)

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 13, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07872306
Lead sponsor
Satellos Bioscience, Inc.
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Satellos Medical Information
Contact
medicalinfo@satellos.com
+1 647-660-1780

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion